InspireMD Inc
NASDAQ:NSPR
Net Margin
InspireMD Inc
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| IL |
|
InspireMD Inc
NASDAQ:NSPR
|
79.8m USD |
-586%
|
|
| JP |
|
Hoya Corp
TSE:7741
|
6.6T JPY |
23%
|
|
| CH |
|
Alcon AG
SIX:ALC
|
31.7B CHF |
11%
|
|
| DK |
|
Coloplast A/S
CSE:COLO B
|
142.1B DKK |
16%
|
|
| US |
|
Align Technology Inc
NASDAQ:ALGN
|
10.3B USD |
11%
|
|
| CH |
|
Ypsomed Holding AG
SIX:YPSN
|
5.5B CHF |
12%
|
|
| UK |
|
ConvaTec Group PLC
LSE:CTEC
|
5B GBP |
9%
|
|
| CN |
|
Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
|
46.8B CNY |
40%
|
|
| US |
|
Merit Medical Systems Inc
NASDAQ:MMSI
|
5.2B USD |
8%
|
|
| CA |
|
Bausch + Lomb Corp
NYSE:BLCO
|
5.1B USD |
-6%
|
|
| JP |
A
|
Asahi Intecc Co Ltd
TSE:7747
|
716.1B JPY |
9%
|
InspireMD Inc
Glance View
InspireMD, Inc. operates as a medical device company, which engages in the development and commercialization of the stent platform technology for the treatment of complex vascular and coronary disease. The firm is focusing on the development and commercialization of its MicroNet stent platform technology for the treatment of vascular and coronary disease. Its MicroNet, a micron mesh sleeve, is wrapped over a stent to provide embolic protection in stenting procedures. Its CGuard carotid embolic prevention system (CGuard EPS) combines its MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. Its MGuard Prime Embolic Protection System (MGuard Prime EPS) is marketed for use in patients with acute coronary syndromes, notably acute myocardial infarction (heart attack) and saphenous vein graft coronary interventions (bypass surgery). The company markets and sells MGuard Prime EPS, a bare-metal cobalt-chromium based stent, for the treatment of coronary disease in the European Union. The company is also developing a neurovascular flow diverter (NGuard), which is an endovascular device.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on InspireMD Inc's most recent financial statements, the company has Net Margin of -585.6%.
You don't have any saved screeners yet